display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
malignant mesothelioma (mMS) - 1st line (L1)
malignant mesothelioma (mMS) - 1st line (L1)
immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 743

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons